On the potential of natural products in the discovery of pharma leads: a case for reassessment.
The central proposition advanced herein is that complex target oriented synthesis, enabled by historic advances in methodology, has enormously expanded the scope of the possible. Accordingly, natural products, a proven long-term source of pharma discovery, re-emerge as potentially valuable elements for synthesis-driven pharma exploitation.
Danishefsky
Samuel
S
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
D000818:Animals; D001688:Biological Products / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D055808:Drug Discovery; D034261:Epothilones / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D018942:Macrolides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D015394:Molecular Structure; D009231:Myxococcales / Q000737:chemistry; D010881:Piperidones / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D013302:Streptomyces / Q000737:chemistry
D001688:Biological Products; D034261:Epothilones; D018942:Macrolides; D010881:Piperidones; C418199:migrastatin